In a nutshell This phase 1 clinical trial will test the safety of blinatumomab (Blincyto) treatment after high-dose melphalan (Alkeran) and autologous stem cell transplant in patients with refractory (unresponsive to treatment) multiple myeloma. The primary outcome will be measured by the number of adverse (negative) effects. The trial is being...
Read More
In a nutshell This early phase 1 clinical trial will test the safety and effectiveness of genetically engineered NY-ESO-1 specific (c259) T-cells cells with or without pembrolizumab (Keytruda) in treating relapsed or refractory (unresponsive to treatment) multiple myeloma. The details NY-ESO-1 is a protein found on many types of cancer cells...
Read More
In a nutshell This phase 3 clinical trial will evaluate the safety and effectiveness of a copanlisib (BAY 80-6946) and rituximab (Rituxan) combination in treating patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by time to disease progression. The details Copanlisib is an inhibitor of...
Read More
In a nutshell This phase 1 clinical trial will test the safety of a JCAR014 engineered T cells and durvalumab (MEDI4736) combination in treating recurrent or refractory (unresponsive to treatment) non-Hodgkin’s lymphoma. The primary outcome will be measured by evaluating the movement of the engineered T cells throughout the body and side...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of ibrutinib (Imbruvica) during and after stem cell transplant in patients with relapsed or refractory diffuse large B-cell lymphoma. The primary outcome will be measured by the time to disease progression. The details Ibrutinib is a drug that stops the growth of...
Read More
In a nutshell This phase 2 clinical trial will test the safety and tolerability of a nivolumab (Opdivo) and 5-azacytidine (Vidaza) combination with or without ipilimumab (Yervoy) in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by the maximum tolerated dose. This trial is...
Read More
In a nutshell This phase 1 clinical trial will test the maximum dose of chimeric antigen receptor (CAR) T-cells in treating advanced lymphoid leukemia and lymphoma. The primary outcome will be measured by the maximum tolerated dose. This trial is being conducted at the University of Texas MD Anderson Cancer Center in Houston, Texas. The details...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of a combination treatment, consisting of ibrutinib (Imbruvica), fludarabine (Fludara), cyclophosphamide (Cytoxan), and obinutuzumab (Gazyva), in treating chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the response to treatment. This trial is being...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of IRD, a combination therapy of ixazomib, lenalidomide, and dexamethasone, after stem cell transplantation, followed by ixazomib or lenalidomide as a maintenance therapy in treating multiple myeloma. The primary outcome will be measured by the disease improvement. The details...
Read More
In a nutshell This phase 2 clinical trial will determine the effectiveness of denintuzumab mafodotin (SGN-CD19A) with RICE chemotherapy in patients with relapsed or refractory (unresponsive to treatment) diffuse large B-cell lymphoma (DLBCL) or stage 3b follicular lymphoma (FL). The primary outcome will be measured by the complete remission...
Read More
In a nutshell This trial examined whether altering the recommended dose of chemotherapy drugs during treatment was beneficial to patients. This trial concluded that altering doses of paclitaxel (Taxol) during chemotherapy could be beneficial to reduce neuropathy in patients with advanced non-small-cell lung cancer. Some...
Read More
In a nutshell This study investigated whether exercise was associated with a reduction in the risk of cardiovascular disease (CVD) in patients with non-metastatic breast cancer (BC). Exercise was found to be linked to a significant reduction in the risk of CVD for this patient group. Some background CVD is a leading cause of death among women with...
Read More
